Medicine and HealthNature Medicine
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
T. B. Dorff, M. S. Blanchard, et al.
A groundbreaking phase 1 study explores PSCA-directed CAR T cells in men with metastatic castration-resistant prostate cancer (mCRPC), revealing potential declines in PSA and radiographic improvements, despite safety challenges. This innovative research was conducted by a dedicated team of authors, including Tanya B. Dorff and M. Suzette Blanchard.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
B. Besse, E. Pons-tostivint, et al.
Medicine and Health
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy
M. J. V. D. Doelen, I. M. Oving, et al.
Medicine and Health
Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
C. E. Brown, J. C. Hibbard, et al.
Medicine and Health
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M. Schuler, K. Cuppens, et al.
